

Lupin receives FDA approval for generic Corgard Tablets

10 October 2017 | News

They are indicated for management of patients with angina pectoris and for the treatment of hypertension



Pharma Major Lupin has announced that it has received final approval for its Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg from the United States Food and Drug Administration (FDA) to market a generic version of US WorldMeds, LLC's Corgard Tablets, 20 mg, 40 mg, and 80 mg.

Lupin's Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg are the AB rated generic equivalent of US WorldMeds, LLC's Corgard® Tablets, 20 mg, 40 mg, and 80 mg. They are indicated for management of patients with angina pectoris and for the treatment of hypertension.

Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg Tablets had annual sales of approximately USD 109.8 million in the US (IMS MAT June 2017).